By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
AdkhabarAdkhabarAdkhabar
Notification Show More
Font ResizerAa
  • Home
  • Automobile
  • Entertainment
  • Esports
  • Food
  • Health
  • Life Style
  • News
  • Technology
  • Travel
Reading: Sanuwave Will Host a Conference Call on November 7, 2025 at 8:30 AM (ET) to Present Q3 2025 Financial Results
Share
Font ResizerAa
AdkhabarAdkhabar
  • Home
  • Automobile
  • Entertainment
  • Esports
  • Food
  • Health
  • Life Style
  • News
  • Technology
  • Travel
Search
  • Home
  • Automobile
  • Entertainment
  • Esports
  • Food
  • Health
  • Life Style
  • News
  • Technology
  • Travel
Follow US
Adkhabar > Blog > Health > Sanuwave Will Host a Conference Call on November 7, 2025 at 8:30 AM (ET) to Present Q3 2025 Financial Results
Sanuwave Will Host a Conference Call on November 7, 2025 at 8:30 AM (ET) to Present Q3 2025 Financial Results
Health

Sanuwave Will Host a Conference Call on November 7, 2025 at 8:30 AM (ET) to Present Q3 2025 Financial Results

GlobeNews Wire
Last updated: 04/11/2025 3:36 AM
GlobeNews Wire
Published: 04/11/2025
Share
SHARE

EDEN PRAIRIE, Minn., Nov. 03, 2025 (GLOBE NEWSWIRE) — Sanuwave Health, Inc. (the “Company” or “Sanuwave”) (NASDAQ: SNWV), a leading provider of next-generation FDA-approved wound care products, will host a live conference call on Friday, November 7, 2025, at 8:30 AM (ET) to present its Q3 2025 financial results.

Telephone access to the call will be available by dialing the following numbers:

Participant Dial-in Information 

Toll Free: 1-800-274-8461

Toll/International: 1-203-518-9814

Conference ID: SANUWAVE

OR click the link for instant telephone access to the event:
https://viavid.webcasts.com/starthere.jsp?ei=1741017&tp_key=73ef3b515a
Materials for the conference call will be included on the Company’s website at
www.sanuwave.com/investors.

A replay will be made available through November 28, 2025:

Toll-Free: 1-844-512-2921 or 1-412-317-6671

Replay Access ID: 11160405

About Sanuwave

Sanuwave Health is focused on the research, development, and commercialization of its patented, non-invasive and biological response-activating medical systems for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures.

Sanuwave’s end-to-end wound care portfolio of regenerative medicine products and product candidates help restore the body’s normal healing processes. Sanuwave applies and researches its patented energy transfer technologies in wound healing, orthopedic/spine, aesthetic/cosmetic, and cardiac/endovascular conditions.

Forward-Looking Statements

This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to future financial results, production expectations, plans for future business development activities and expectations regarding the impact of changes in tariff rates. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with regulatory oversight, the Company’s ability to manage its capital resources, competition and the other factors discussed in detail in the Company’s periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement.

Contact:

investors@sanuwave.com

Jetcraft launches Special Missions division for defense and government aircraft
Heidi Hunter Appointed New Vice Chair of the Board of Directors of Bavarian Nordic
TraceLink Delivers Intelligent Productivity Gains with OPUS Platform Expansion
GLOBAL TRANSFORMATION LEADERS JOIN AOKAH ADVISORY BOARD
Novo Nordisk A/S: CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in New England Journal of Medicine
TAGGED:(et)20258:30callconferencefinancialhostNasdaq:SNWVnewsnovemberpresentresultssanuwaveUS80303D3052will
Share This Article
Facebook Email Print
- Advertisement -

Follow US

Find US on Social Medias
FacebookLike
XFollow
YoutubeSubscribe

Weekly Newsletter

Subscribe to our newsletter to get our newest articles instantly!
Popular News
Perseus Brings Its Flagship PEGASUS Automotive Hypervisor to Infineon AURIX TC4Dx Platform
News

Perseus Brings Its Flagship PEGASUS Automotive Hypervisor to Infineon AURIX TC4Dx Platform

11/03/2026
P2P.org Appoints Betsabe Botaitis as Chief Financial Officer
2025 Chengdu Open Rowing Regatta held in Xinjin
Teva to Present at the 8th Annual Evercore Healthcare Conference, the Piper Sandler 37th Annual Healthcare Conference and Citis 2025 Global Healthcare Conference in December
Kikkoman launches ‘The Kikkoman Manga’ to accelerate the switch to its soy sauce by more restaurants in India
- Advertisement -
- Advertisement -
- Advertisement -

Categories

  • Automobile
  • Entertainment
  • E-Sports
  • Food
  • Health
  • Technology
  • LifeStyle
  • Travel

About Us

Through our news networks, we raise millions of users' awareness. We are among the world's most reputable news networks.
Quick Link
Top Categories
  • Entertainment

Subscribe US

Subscribe to our newsletter to get our newest articles instantly!

AdkhabarAdkhabar
Copyright © 2021 - 2025 AdKhabar. All Rights Reserved. POWERED BY Life Care News.
Join Us!
Subscribe to our newsletter and never miss our latest news, podcasts etc..
Zero spam, Unsubscribe at any time.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?